Andere Sprachen Rezolute, Inc.

Aktien

A2QEWP

US76200L3096

RZLT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
2,6 ^USD	-10,03 %		-21,21 %	+161,96 %

18.04.	REZOLUTE, INC. : JonesTrading Institutional Services bekräftigt seine Kaufempfehlung	ZM
06.03.	Rezolute, Inc. meldet Validierung des potenziellen Einsatzes von RZ358 zur Behandlung der Hypoglykämie bei Nicht-Inselzelltumoren (NICTH)	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

REZOLUTE, INC. - PHASE 2 RIZE STUDY SUB-ANALYSES TO BE PRESENTED AT THE 2024 PEDIATRIC ENDOCRINE SOCIETY ANNUAL MEETING	24.04.
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting	23.04.
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting	23.04.
REZOLUTE REPORTS VALIDATION OF THE POTENTIAL USE OF RZ358 FOR TREATMENT OF NON-ISLET CELL TUMOR HYPOGLYCEMIA	07.03.
Rezolute : Corporate Presentation – March 2024	06.03.
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)	06.03.
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)	06.03.
Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	06.03.
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13.02.
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update	13.02.
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer	24.01.
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer	24.01.
Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer	24.01.
REZOLUTE RECEIVES INNOVATION PASSPORT DESIGNATION FROM THE U.K. INNOVATIVE LICENSING AND ACCESS PATHWAY STEERING GROUP FOR RZ358	24.01.
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	23.01.
Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	23.01.
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism	14.12.
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)	13.12.
Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema	13.12.
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"	24.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Rezolute, Inc.

Aktien

A2QEWP

US76200L3096

RZLT

Andere Sprachen

Filter